Alzheimer’s disease is a progressive brain disease that destroys memory, thinking ability, and eventually the capacity to carry out basic daily tasks. It is the most common cause of dementia, accounting for the majority of cases, and an estimated 6.9 million Americans age 65 and older are living with it today. Alzheimer’s is not a normal part of aging, and it is currently the fifth-leading cause of death among Americans 65 and older.
Alzheimer’s Is Not the Same as Dementia
One of the most common points of confusion is the relationship between Alzheimer’s and dementia. Dementia is not a disease itself. It’s an umbrella term describing a wide range of symptoms that interfere with a person’s ability to perform everyday activities on their own, including memory loss, confusion, and changes in personality. Alzheimer’s disease is one specific cause of dementia, and the most common one, but other conditions like vascular disease, Lewy body disease, and frontotemporal degeneration can also cause dementia. When someone is diagnosed with Alzheimer’s, they have dementia, but not everyone with dementia has Alzheimer’s.
What Happens Inside the Brain
Alzheimer’s involves two types of abnormal protein buildup in the brain. The first is amyloid plaques: sticky fragments of a protein called amyloid-beta that clump together between nerve cells. In a healthy brain, these fragments are broken down and cleared away. In Alzheimer’s, they accumulate into plaques, particularly near the junctions where nerve cells communicate with each other. These clumps, especially smaller soluble clusters called oligomers, are considered the most toxic form. They disrupt the signals nerve cells send to one another, interfering with memory and thought.
The second hallmark is tau tangles. Tau is a protein that normally acts like a structural scaffold inside nerve cells, holding together the tiny tubes that transport nutrients along the cell. In Alzheimer’s, tau becomes chemically altered and detaches from these tubes, causing them to collapse. The altered tau proteins then clump together into tangled threads inside the cell. These tangles block the transport of nutrients and chemicals that nerve cells need to survive and communicate. Over time, the combined effect of plaques and tangles causes nerve cells to die, and the brain physically shrinks.
These two processes appear to work together. Research published in Cell Death & Disease describes how amyloid and tau act synergistically to damage connections between nerve cells and impair memory, rather than one simply triggering the other in a simple chain reaction.
Early Warning Signs vs. Normal Aging
Everyone forgets things occasionally, especially with age. Misplacing your car keys, struggling to find a word but remembering it later, or blanking on an acquaintance’s name are all considered normal age-related memory changes. What separates early Alzheimer’s from ordinary forgetfulness is the severity, pattern, and progression of memory problems.
Warning signs that suggest something beyond normal aging include:
- Getting lost in a familiar neighborhood, not just taking a wrong turn
- Using unusual words for familiar objects, like calling a watch a “hand clock”
- Forgetting the name of a close family member or friend, not just an acquaintance
- Forgetting old, well-established memories, not just recent events
- Being unable to complete common tasks independently, like paying bills or following a recipe you’ve used for years
The distinction matters because early Alzheimer’s symptoms tend to worsen steadily over months, while normal age-related lapses stay relatively stable and don’t significantly interfere with daily life.
How the Disease Progresses
Alzheimer’s develops slowly and worsens over years. On average, people live between 3 and 11 years after diagnosis, though some live 20 years or more. The disease moves through recognizable stages, though the pace varies widely from person to person.
Brain changes actually begin years or even decades before any symptoms appear. This is called the preclinical stage, and it’s only detectable through specialized research testing. The person feels completely normal.
The first noticeable stage involves mild cognitive impairment: subtle memory and thinking changes that are real but not severe enough to disrupt work or relationships. Someone might have occasional trouble remembering recent conversations or keeping track of appointments.
In the mild dementia stage, problems become more apparent. People may struggle to find the right words, get lost in familiar places, misplace belongings in unusual spots, or lose motivation to complete tasks. Irritability and personality changes often emerge. This is frequently when a diagnosis is made.
Moderate dementia brings deepening confusion. People lose track of where they are, what day it is, or what season it is. They need increasing help with daily activities like dressing, bathing, and managing finances. Judgment deteriorates noticeably.
In severe dementia, communication becomes minimal or impossible. Physical abilities decline until a person may be unable to sit up without support, swallow food, or control bladder and bowel function. At this stage, full-time care is necessary.
Risk Factors and Genetics
Alzheimer’s rarely has a single cause. In most cases, it results from a combination of genetic, lifestyle, and environmental factors. The best-known genetic risk factor is a gene called APOE, which helps make a protein involved in carrying cholesterol through the bloodstream. One variant of this gene, APOE e4, increases the risk of developing Alzheimer’s and is associated with an earlier age of onset. About 15% to 25% of people carry one copy of this variant, and 2% to 5% carry two copies. Having two copies raises the risk significantly, but carrying the gene does not guarantee you will develop the disease. Some people with APOE e4 never get Alzheimer’s.
Modifiable factors also play a role. Exercise, diet, smoking, education level, and cardiovascular health all influence risk. Rates of dementia vary across racial and ethnic groups, reflecting differences in both genetics and external influences like access to education, income, and environmental exposures. This means that while you can’t change your genes, lifestyle choices genuinely affect your overall risk.
How Alzheimer’s Is Diagnosed
Traditional diagnosis relies on clinical assessment, including memory and thinking tests, medical history, and neurological exams. The limitation is that these approaches often identify the disease at a relatively late stage, when significant brain damage has already occurred.
More precise tools now exist. Brain imaging with PET scans uses specialized tracers that bind to amyloid plaques, allowing doctors to see and measure protein deposits in a living brain. Three of these tracers are FDA-approved. Spinal fluid analysis can also detect Alzheimer’s by measuring levels of amyloid and tau proteins. A specific pattern of low amyloid-beta and elevated tau in the spinal fluid is considered the biochemical signature of the disease. These biomarker tests are primarily used in specialized clinical settings and are becoming more central to diagnosis, especially for people considering newer treatments.
Current Treatment Options
There is no cure for Alzheimer’s, but treatments have advanced significantly. Older medications help manage symptoms by boosting chemical signals between surviving nerve cells, which can temporarily improve memory and thinking ability.
A newer class of treatments targets the disease process itself. These are infusion-based therapies designed to clear amyloid plaques from the brain. The FDA has approved treatments including donanemab (sold as Kisunla) and lecanemab, both of which work by binding to amyloid deposits and helping the immune system remove them. In clinical trials, treatment was adjusted based on how much plaque reduction PET scans showed at regular intervals. These therapies slow cognitive decline rather than stop or reverse it, and they carry risks including brain swelling and small brain bleeds that require monitoring with regular brain scans. They are most relevant for people in the early stages of the disease who have confirmed amyloid buildup.